A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine
Open Access
- 11 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12), e49704
- https://doi.org/10.1371/journal.pone.0049704
Abstract
Concern for a pandemic caused by a newly emerged avian influenza A virus has led to clinical trials with candidate vaccines as preparation for such an event. Most trials have involved vaccines for influenza A (H5N1), A (H7N7) or A (H9N2). To evaluate dosage-related safety and immunogenicity of an inactivated influenza A (H7N7) vaccine in humans. One hundred twenty-five healthy young adults were randomized to receive two doses intramuscularly of placebo or 7.5, 15, 45 or 90 µg of HA of an inactivated subunit influenza A (H7N7) vaccine (25 per group), four weeks apart. Reactogenicity was evaluated closely for one week and for any adverse effect for six months after each dose. Serum hemagglutination-inhibiting and neutralizing antibody responses were determined four weeks after each dose and at six months. Reactogenicity evaluations indicated the vaccinations were well tolerated. Only one subject developed a ≥4-fold serum hemagglutination-inhibition (HAI) antibody response and a final titer of ≥1∶40 four weeks after dose two and only five subjects developed a neutralizing antibody rise and a final titer of ≥1∶40 in tests performed at a central laboratory. Four of the five were given the 45 or 90 µg HA dosage. A more sensitive HAI assay at the study site revealed a dose-response with increasing HA dosage but only 36% in the 90 µg HA group developed a ≥4-fold rise in antibody in this test and only one of these achieved a titer of ≥1∶32. This inactivated subunit influenza A (H7N7) vaccine was safe but poorly immunogenic in humans. ClinicalTrials.gov NCT00546585Keywords
This publication has 27 references indexed in Scilit:
- A distinct lineage of influenza A virus from batsProceedings of the National Academy of Sciences, 2012
- A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and MonkeysJournal of Virology, 2010
- A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsVaccine, 2009
- Past, Present, and Possible Future Human Infection with Influenza Virus A Subtype H7Emerging Infectious Diseases, 2009
- A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccineVaccine, 2009
- Development and Evaluation of an Influenza Virus Subtype H7N2 Vaccine Candidate for Pandemic PreparednessClinical and Vaccine Immunology, 2007
- Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsVaccine, 2007
- Characterization of the 1918 influenza virus polymerase genesNature, 2005
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Avian Influenza A (H5N1) in 10 Patients in VietnamNew England Journal of Medicine, 2004